U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-Q

(Ma	ark One)
V	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended <u>September 30, 2008</u>
	TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to
	Commission File Number: <u>1-10526</u>
	UNITED-GUARDIAN, INC.
	(Exact Name of Registrant as Specified in Its Charter)
	Delaware 11-1719724
	(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
	230 Marcus Boulevard, Hauppauge, New York 11788 (Address of Principal Executive Offices)
	(631) 273-0900 (Registrant's Telephone Number)
	(Former name, former address and former fiscal year, if changed since last report)
by	Indicate by check mark whether the registrant (1) has filed all reports required to be filed Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such

shorter period that the registrant was required to file such reports), and (2) has been subject to such

Yes 🗹

No □

filing requirements for the past 90 days.

non-accelerated filer, or a smaller repor	ting company. See definitions of "large accelerated filer" company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Non-accelerated filer Accelerated filer Smaller reporting company	☐ (Do not check if a smaller reporting company) ☐ ☑
Indicate by check mark whether of the Exchange Act.)	the registrant is a shell company (as defined in Rule 12b-2 $ \text{Yes } \ \square \text{No} \ \ \boxed{\square} $
Indicate the number of shares outs the latest practicable date:	standing of each of the issuer's classes of common stock, as of
· · ·	common stock, par value \$.10 per share s of November 1, 2008)

UNITED-GUARDIAN, INC. INDEX

	Page No.
Part I. FINANCIAL INFORMATION	
Item 1 - Condensed Financial Statements	
Consolidated Statements of Income - Three and Nine Months ended September 30, 2008 and 2007 (unaudited)	2
Consolidated Balance Sheets – September 30, 2008 (unaudited) and December 31, 2007	3-4
Consolidated Statements of Cash Flows – Nine months ended September 30, 2008 and 2007 (unaudited)	5
Notes to Consolidated Financial Statements (unaudited)	6-13
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	13-19
Item 3 - Quantitative and Qualitative Disclosures About Market Risk	19
Item 4T - Controls and Procedures	19
Part II. OTHER INFORMATION	
Item 1 - Legal Proceedings	19
Item 1A - Risk Factors	19
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3 - Defaults Upon Senior Securities	20
Item 4 - Submission of Matters to a Vote of Security Holders	20
Item 5 - Other Information	20
Item 6 - Exhibits and Reports On Form 8-K	20
Signatures	21

Part I. FINANCIAL INFORMATION

ITEM 1. Condensed Financial Statements

CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

	NINE MONTHS ENDED SEPTEMBER 30, 2008 2007			NTHS ENDED MBER 30, <u>2007</u>
Revenue from continuing operations:				
Net sales	\$ <u>9,500,563</u>	\$ <u>9,408,156</u>	\$ <u>3,498,325</u>	\$ <u>2,647,450</u>
Costs and expenses:				
Cost of sales	4,169,106	3,767,963	1,631,927	973,992
Operating expenses	<u>1,980,430</u>	1,892,257	628,798	<u>559,113</u>
	<u>6,149,536</u>	<u>5,660,220</u>	<u>2,260,725</u>	<u>1,533,105</u>
Operating income from continuing				
operations	3,351,027	3,747,936	1,237,600	1,114,345
Other income (expense):				
Investment income	362,161	425,935	113,387	140,499
(Loss) gain on sale of equipment	(7,763)	5,000		
Other	<u>(1,868</u>)	(42)	_(493)	
	<u>352,530</u>	430,893	112,894	140,499
Income from continuing energtions before				
Income from continuing operations before income taxes	3,703,557	4,178,829	1,350,494	1,254,844
Provision for income taxes	<u>1,216,500</u>	<u>1,482,300</u>	<u>439,000</u>	<u>442,700</u>
Income from continuing operations	2,487,057	2,696,529	911,494	812,144
Loss from discontinued operations, net of				
income tax benefit		<u>(18,009</u>)		<u>(28,939</u>)
Net income	\$ <u>2,487,057</u>	\$ <u>2,678,520</u>	\$ <u>911,494</u>	\$ <u>783,205</u>
Earnings per common share				
(Basic and Diluted): Continuing operations	\$ 0.50	\$ 0.54	\$ 0.18	\$ 0.16
Discontinued operations	ψ 0.50	ψ 0.34	φ 0.10	ψ 0.10
Total—Basic and diluted	\$ 0.50	\$ 0.54	\$ 0.18	\$ 0.16
Weight and a second place of the control of the con	4.040.400	1.044.463	4.040.400	4 0 4 0 4 0 0
Weighted average shares – basic	<u>4,946,439</u>	<u>4,944,439</u>	<u>4.946,439</u>	<u>4,946,439</u>
Weighted average shares – diluted	<u>4,946,439</u>	<u>4,945,746</u>	<u>4,946,439</u>	<u>4,946,439</u>

CONSOLIDATED BALANCE SHEETS

<u>ASSETS</u>	SEPTEMBER 30, 2008 (UNAUDITED)	DECEMBER 31,
Current assets:	,	
Cash and cash equivalents	\$ 4,410,205	\$ 4,555,388
Temporary investments	331,636	555,829
Marketable securities	7,208,570	7,465,419
Accounts receivable, net of allowance for doubtful accounts of \$19,316 at September 30, 2008 and \$30,000 at December 31, 2007	1,834,006	1,278,386
Inventories (net)	1,085,413	1,188,222
Prepaid expenses and other current assets	178,022	427,712
Deferred income taxes	222,970	222,970
Assets of discontinued operations Total current assets	 15,270,822	<u>64,619</u> <u>15,758,545</u>
Property, plant and equipment:		
Land	69,000	69,000
Factory equipment and fixtures	3,282,102	3,233,621
Building and improvements	2,368,606	2,335,975
Waste disposal plant	<u>133,532</u>	133,532
	5,853,240	5,772,128
Less: Accumulated depreciation Total property, plant and equipment, net	4,929,625 923,615	4,818,731 953,397
Other assets Other Pension asset Total other assets TOTAL ASSETS	218,543 <u>284,794</u> <u>503,337</u> \$ 16,697,774	148,430 <u>174,096</u> <u>322,526</u> \$ 17,034,468
	+ - 2,22.,	* <u>···,···</u>

CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities	SEPTEMBER 30, 2008 (UNAUDITED)	I	DECEMBER 31, 2007
Dividends payable	\$ 	\$	1,385,003
Accounts payable	230,596		123,290
Current loans payable	7,988		7,988
Accrued expenses	932,663		794,186
Liabilities of discontinued operations Total current liabilities	 1,171,247		<u>47,386</u> <u>2,357,853</u>
Loans payable	666		6,657
Deferred income taxes Total long term liabilities	37,564 38,230		139,862 146,519
Stockholders' equity:			
Common stock \$.10 par value, authorized, 10,000,000 shares; 5,008,639 shares issued, and 4,946,439 shares outstanding	500,864		500,864
Capital in excess of par value	3,819,480		3,819,480
Accumulated other comprehensive loss	(313,335)		(120,018)
Retained earnings	11,840,918		10,689,400
Treasury stock, at cost; 62,200 shares	(359,630)		(359,630)
Total stockholders' equity	<u>15,488,297</u>		14,530,096
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ <u>16,697,774</u>	\$	<u>17,034,468</u>

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

NINE MONTHS ENDED September 30,

	<u>2008</u>	<u>2007</u>
Cash flows from operating activities:		
Income from continuing operations	\$ 2,487,057	\$ 2,696,529
Adjustments to reconcile net income to net cash		
provided by operating activities:		
Depreciation and amortization	160,055	149,717
Realized gain on sales of marketable securities	(438)	
Loss (gain) on sale of equipment	7,763	(5,000)
Reduction in allowance for bad debts	(10,684)	
Increase (decrease) in cash resulting from		
changes in operating assets and liabilities:		
Accounts receivable	(544,936)	266,344
Inventories	102,809	472,038
Prepaid expenses and other current		
and non-current assets	(49,960)	19,302
Accounts payable	107,306	23,717
Accrued pension costs	(110,698)	(57,973)
Accrued expenses and taxes payable	329,447	127,069
Loss from discontinued operations		(18,009)
Net cash provided by (used in) discontinued operations	<u>17,233</u>	<u>(127,901</u>)
Net cash provided by operating activities	<u>2,494,954</u>	<u>3,545,833</u>
Cash flows from investing activities:		
Acquisition of property, plant and equipment	(107,457)	(263,237)
Proceeds from sale of equipment	7,988	5,000
Net change in temporary investments	224,193	(20,895)
Proceeds from sale of marketable securities	1,550,000	300,000
Purchase of marketable securities	(1,588,328)	<u>(524,975</u>)
Net cash provided by (used in) investing activities	86,396	<u>(504,107</u>)
Cash flows from financing activities:		
Payment of long term debt	(5,991)	(5,991)
Proceeds from exercise of stock options	(0,001)	14,157
Dividends paid	(2,720,542)	(2,422,755)
Net cash used in financing activities	(2,726,533)	(2,414,589)
Net (decrease) increase in cash and cash equivalents	(145,183)	627,137
Cash and cash equivalents at beginning of period	4,555,388	<u>2,813,096</u>
Cash and cash equivalents at end of period	\$ <u>4,410,205</u>	\$ 3,440,233
Cash and additional and all of botton	Ψ <u>1,110,200</u>	ψ <u>σ,ππο,2σσ</u>

See notes to condensed consolidated financial statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Eastern Chemical Corporation ("Eastern"). Significant intercompany transactions have been eliminated. Substantially all of Eastern's assets were sold in December 2007 (see Note 11).

2. Basis of Presentation

In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position as of September 30, 2008 and the results of operations for the three and nine months ended September 30, 2008 and 2007. The accounting policies followed by the Company are set forth in the Company's financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2007.

The results of operations for the three and nine months ended September 30, 2008 are not necessarily indicative of the results to be expected for the full year.

3. Stock-Based Compensation

At September 30, 2008, the Company had a stock-based compensation plan for its employees and Directors, which is more fully described in the Company's Annual Report on Form 10-K for the year ended December 31, 2007.

The Company follows the Financial Accounting Standards Board ("FASB") Statement of Financial Accounting Standards ("SFAS") No. 123R, which requires that the fair value of all share-based payments to employees, including grants of employee stock options, be recognized as expense in the financial statements.

As of September 30, 2008 the Company had no share-based awards outstanding and exercisable and did not grant any options during the nine months ended September 30, 2008.

As of September 30, 2008 there was no remaining unrecognized compensation cost related to the non-vested share-based compensation arrangements granted under the Company's plans.

The Company did not record any compensation expense under the provisions of FAS 123R during the nine- and three-month periods ended September 30, 2008 and 2007.

The Company received proceeds of \$14,157 from the exercise of options for a total of 4,300 shares that were exercised during the nine months ended September 30, 2007. The intrinsic value of those shares was \$40,217. The Company did not receive any proceeds from the exercise of options during the nine months ended September 30, 2008.

4. Recent Accounting Pronouncements

In October 2008, the FASB issued FASB Staff Position FAS 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active" ("FSP 157-3"), which clarified the application of FAS 157 and demonstrated how the fair value of a financial asset is determined when the market for that financial asset is inactive. FSP 157-3 was effective upon issuance. The implementation of this standard did not have an impact on the Company's financial position.

Effective January 1, 2008, the Company adopted SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS 159"). This statement provides companies with an option to report selected financial assets and liabilities at fair value. As of September 30, 2008, the Company has not elected to use the fair value option allowed by SFAS 159. The adoption of SFAS 159 did not have a material effect on the Company's financial position, results of operations, cash flows or financial statement disclosures.

In December 2007, the FASB issued Statement No. 141 (revised), "Business Combinations" ("SFAS 141 (R)"). The standard changes the accounting for business combinations including the measurement of acquirer shares issued in consideration for a business combination, the recognition of contingent consideration, the accounting for pre-acquisition gain and loss contingencies, the recognition of capitalized in-process research and development, the accounting for acquisition-related restructuring cost accruals, the treatment of acquisition related transaction costs and the recognition of changes in the acquirer's income tax valuation allowance. SFAS 141(R) is effective for fiscal years beginning after December 15, 2008, with early adoption prohibited. The Company does not expect SFAS 141(R) to have a significant impact on the Company's financial position, and will evaluate the impact in the event of an acquisition.

In December 2007, the FASB issued Statement No. 160, "Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51" ("SFAS 160"). The standard changes the accounting for noncontrolling (minority) interests in consolidated financial statements including the requirements to classify noncontrolling interests as a component of consolidated stockholders' equity, and the elimination of "minority interest" accounting in results of operations with earnings attributable to noncontrolling interests reported as part of consolidated earnings. Additionally, SFAS 160 revises the accounting for both increases and decreases in a parent's controlling ownership interest. SFAS 160 is effective for fiscal years beginning after December 15, 2008, with early adoption prohibited. The Company does not expect the adoption of SFAS 160 to have a significant impact on the Company's financial position.

5. Investments

Effective January 1, 2008, the Company adopted SFAS No. 157, "Fair Value Measurements" ("SFAS 157"), for assets and liabilities measured at fair value on a recurring basis. SFAS 157 accomplishes the following key objectives:

- Defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date;
- Establishes a three-level hierarchy ("Valuation Hierarchy") for fair value measurements;
- Requires consideration of the Company's creditworthiness when valuing liabilities; and

Expands disclosures about instruments measured at fair value.

The Valuation Hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. A financial instrument's categorization within the Valuation Hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of the Valuation Hierarchy and the distribution of the Company's financial assets within it are as follows:

- Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
- Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following available-for-sale securities are re-measured to fair value on a recurring basis and are valued using level 1 inputs and the market approach as defined by SFAS 157:

<u>September 30, 2008</u>	<u>Cost</u>	<u>Fair Value</u>	Unrealized Gain/(Loss)
Available for Sale: U.S. Treasury and agencies Mature within 1 year Mature 1-5 years Total US Treasury and agencies	\$ 900,092 1,700,585 \$ 2,600,677	\$ 903,657 1,718,912 \$ 2,622,569	\$ 3,565
Fixed income mutual funds Equity and other mutual funds	4,639,289 <u>238,902</u> \$ <u>7,478,868</u>	4,371,535 <u>214,466</u> \$ <u>7,208,570</u>	(267,754) (24,436) \$ (270,298)
December 31, 2007	Cost	<u>Fair Value</u>	Unrealized <u>Gain/(Loss)</u>
Available for Sale: U.S. Treasury and agencies Mature within 1 year Mature 1-5 years Total US Treasury and agencies	\$ 949,354 1,803,298 \$ 2,752,652	\$ 960,329 1,835,253 \$ 2,795,582	\$ 10,975 31,955 \$ 42,930
Fixed income mutual funds Equity and other mutual funds	4,452,052 <u>235,399</u> \$ <u>7,440,103</u>	4,404,080 <u>265,757</u> \$ <u>7,465,419</u>	(47,972) <u>30,358</u> \$ <u>25,316</u>

In addition, the Company holds temporary investments, which consist of one-year certificates of deposit, which totaled \$331,636 as of September 30, 2008 and \$555,829 as of December 31, 2007.

6. Inventories - Net

	September 30, <u>2008</u>	December 31, 2007
Inventories consist of the following:	\$ 396,227	\$ 359,730
Raw materials and work in process	689,186	<u>828,492</u>
Finished products	\$ 1,085,413	\$ 1,188,222

As of September 30, 2008 and December 31, 2007 the Company had reserves of \$39,000 for slow moving and obsolete inventory.

7. Supplemental Financial Statement Information

For purposes of the Consolidated Statement of Cash Flows, the Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.

Cash payments for taxes were \$1,025,530 and \$1,460,728 for the nine months ended September 30, 2008 and 2007, respectively. Payments for interest for the nine months ended September 30, 2008 amounted to \$1,868. There were no payments for interest during the nine months ended September 30, 2007.

Research and development expenses amounted to \$324,608 and \$332,078 for the nine months ended September 30, 2008 and 2007, respectively, and are included in operating expenses.

8. Line of Credit

The Company had a line of credit agreement with JP Morgan Chase Bank for borrowings of up to \$2,000,000 at an interest rate of 1.0% below the Prime Rate, which expired June 30, 2008. The Company decided that the cost of maintaining the line of credit was no longer justified, since the Company had no foreseeable need for the line. For that reason the Company has chosen not to renew it.

9. Income Taxes

The Company's tax provision is based on its estimated annual effective tax rate.

The Company follows the provisions of FIN 48. The Company continues to fully recognize its tax benefits, which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. As of December 31, 2007 and September 30, 2008, the Company did not have any unrecognized tax benefits.

The Company files consolidated Federal income tax returns in the U.S., and separate income tax returns in New York State. The Company is subject to examination by the Internal Revenue Service for years 2005 through 2007 and by New York State for years 2005 through 2007.

The Company's policy is to recognize interest and penalties in Other Expense.

10. Comprehensive Income

The components of comprehensive income are as follows:

	Nine months ended September 30, 2008 2007			onths ended ember 30 <u>2007</u>
Net income	\$ <u>2,487,057</u>	\$ <u>2,678,520</u>	\$ <u>911,494</u>	\$ <u>783,205</u>
Other comprehensive income				
Unrealized (loss) gain on marketable securities during period	(295,615)	52,548	(213,246)	114,246
Income tax (benefit) expense related to other comprehensive income	(102,298)	<u>19,500</u>	<u>(73,783</u>)	42,500
Other comprehensive income, net of tax Comprehensive income	(193,317) \$ <u>2,293,740</u>	<u>33,048</u> \$ <u>2,711,568</u>	(139,463) \$ 772,031	71,246 \$ <u>854,451</u>

Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities and liability for pension benefit net of the related tax effect.

11. Discontinued Operations

On December 11, 2007 the Company completed the sale of substantially all of the assets of its Eastern Chemical Corporation ("Eastern") subsidiary. The assets of Eastern were sold for \$266,759, which resulted in a gain during 2007 of \$84,361 (net of taxes of \$45,396). As a result of the sale, Eastern is classified as discontinued operations for all periods presented.

The table below sets forth the results of operations of Eastern for the periods indicated. A portion of the Company's overhead was previously allocated to Eastern in determining segment information in previous financial statements. The results below do not include any allocated or common overhead expenses. The Company does not expect to incur additional losses associated with Eastern. Its remaining assets and liabilities were fully liquidated in the second quarter of 2008.

The results of operations of Eastern for the nine and three months ended September 30, 2007, and the financial position as of September 30, 2008 and December 31, 2007, were as follows:

Results of Operations:

	Nine months ended September 30, 2007	Three months ended September 30, 2007
Revenue	\$ 663,358	\$ 179,131
Less:		
Cost of goods sold	(448,921)	(128,597)
General and administrative	<u>(243,246</u>)	<u>(96,773</u>)
Income before income taxes	(28,809)	(46,239)
Income tax	<u>(10,800</u>)	<u>(17,300</u>)
Loss from discontinued operations	\$ <u>(18,009</u>)	\$ <u>(28,939</u>)

Financial Position:

	S	eptember 30 <u>2008</u>	D	ecember 31, <u>2007</u>
Net current assets:				
Current assets	\$		\$	64,619
Current liabilities				(47,386)
Net current assets of discontinued operations	\$	<u></u>	\$	17,233

12. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the nine and three months ended September 30, 2008 and 2007:

		onths ended ember 30,	Three months ended September 30,		
	<u>2008</u> '	2007	<u>2008</u>	<u>2007</u>	
Numerator:					
Income from continuing operations	\$ 2,487,057	\$ 2,696,529	\$ 911,494	\$ 812,144	
Loss from discontinued operations Net income	\$ <u>2,487,057</u>	<u>(18,009)</u> \$ <u>2,678,520</u>	\$ <u>911,494</u>	(28,939) \$ 783,205	
Denominator:					
Denominator for basic earnings per share (weighted average shares)	4,946,439	4,944,439	4,946,439	4,946,439	
Effect of dilutive securities: Employee stock options		1,307			
Denominator for diluted earnings per share					
(adjusted weighted-average shares) and assumed conversions	<u>4,946,439</u>	<u>4,945,746</u>	<u>4,946,439</u>	4,946,439	
Basic and diluted earnings per share:					
Continuing operations	\$ 0.50	\$ 0.54	\$ 0.18	\$ 0.16	
Discontinued operations Total—Basic and diluted	\$ 0.50	\$ <u>0.54</u>	\$ 0.18	\$ <u>0.16</u>	

13. Defined Benefit Pension Plan

The Company sponsors a non-contributory defined benefit plan ("Plan") for its employees and adopted FAS 158 effective December 31, 2006. A measurement period from October 1, 2006 to October 1, 2007 has been used for the year ended December 31, 2007. Due to curtailment of the Plan at December 31, 2007, the Company reported the effect of the curtailment through December 31, 2007. The following table sets forth the components of the projected net periodic benefit costs for the year ending December 31, 2008 and the actual net periodic benefit cost for the year ended December 31, 2007.

	<u>2008</u>	<u>2007</u>
	(projected)	
Service cost – benefit earned	\$	\$ 126,132
Interest cost – projected benefit obligation	141,221	144,358
Expected return on plan assets	(185,789)	(137,632)
Amortization of net loss		49,051
Effects of special events		24,537
Amortization of prior service costs		7,461
	\$ (44,568)	\$ 213,907
Effect of curtailment of the Plan		<u>(11,112</u>)
Net periodic benefit costs	\$ <u>(44,568</u>)	\$ <u>202,795</u>

The Company made cash contributions totaling \$77,272 and \$200,000 to the Plan during the nine-month periods ended September 30, 2008 and 2007, respectively. The Company recorded income of \$33,426 for the nine months ended September 30, 2008 and expense of \$142,027 for net periodic benefit costs for the nine months ended September 30, 2007.

As of December 31, 2007 the Company froze future benefit accruals to the Plan while it investigated the advisability of replacing the Plan with a defined contribution plan, to be coordinated with, and be part of, the Company's 401(k) plan. On February 19, 2008, the Company decided to terminate the Plan, subject to regulatory approval, and has begun taking the steps necessary to do so. The Company expects to obtain regulatory approval in 2009.

Upon termination of the Plan, non-vested benefits will become fully vested. Any resulting gain will first be offset against any existing net loss included in accumulated other comprehensive income.

Under FASB Statement No. 88, "Employers' Accounting for Settlements and Contributions of Defined Benefit Pension Plans and for Termination Benefits", if the net effect of a termination is a gain, the gain is to be recognized when the termination occurs, which would be the date the employees are terminated or the date the Plan is terminated.

The Company has accrued \$150,000 for the nine months ended September 30, 2008 for the proposed new defined contribution plan.

14. Geographic and Other Information

The Company operates in one business segment and serves several end markets.

(a) Gross Revenues

	Nine months ended September 30,			Three months ended September 30,		
End Markets Served	2008		<u>2007</u>	<u>2008</u>		<u>2007</u>
Personal care	\$ 6,142,795	\$	6,155,804	\$ 2,338,909	\$	1,728,661
Pharmaceuticals	1,956,805		1,996,442	710,943		463,116
Medical	1,513,938		1,339,371	499,439		448,175
Industrial	<u>81,432</u>		<u>94,381</u>	<u>29,746</u>		<u>35,866</u>
	<u>9,694,970</u>		9,585,998	<u>3,579,037</u>		2,675,818
Less net discounts						
and allowances	<u>(194,407</u>)		<u>(177,842</u>)	<u>(80,712</u>)		<u>(28,368</u>)
	\$ <u>9,500,563</u>	\$	<u>9.408,156</u>	\$ <u>3,498,325</u>	\$	<u>2,647,450</u>

(b) Geographic Information

		Nine months ended September 30,						
	2	2008			2007			
	Revenues	Long-Lived <u>Assets</u>		<u>Revenues</u>		L	Long-Lived <u>Assets</u>	
United States	\$ 4,077,529	\$	923,615	\$	4,031,588	\$	962,313	
France	1,126,561				994,877			
Other countries	4,296,473				4,381,691			

\$ <u>923,615</u>

\$ 9,408,156

(c) Major Customers (revenues)

	Nine months ended September 30,				
	2008		2007		
Customer A	\$ 4,306,514	\$	4,208,477		
Customer B	954,301		758,295		
All other customers	4,239,748		4,441,384		
	\$ <u>9,500,563</u>	\$	<u>9,408,156</u>		

\$ 9,500,563

At September 30, 2008 customers A and B represented 59.2% and 0.5% respectively, of total accounts receivable. At September 30, 2007 customers A and B represented 27.1% and 16.3%, respectively, of total accounts receivable.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-

looking statements may be identified by the use of such words as "believes," "may," "will," "should," "intends," "plans," "estimates," or "anticipates" or other similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.

Accordingly, results actually achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

OVERVIEW

The Company is a Delaware corporation that conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. All of the products that the Company manufactures, with the exception of its Renacidin Irrigation, are produced at its facility in Hauppauge, New York, and are marketed through marketing partners, distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important personal care product line is its LUBRAJEL® line of water-based moisturizing and lubricating gels. It also sells two pharmaceutical products for urological uses. Those products are sold primarily through the major drug wholesalers, which in turn sell the products to pharmacies, physicians, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the Veteran's Administration.

The Company's pharmaceutical products are distributed primarily in the United States. Its personal care products are marketed worldwide primarily by its marketing partners, the largest of which is International Specialty Products Inc. ("ISP"). Approximately one-half of the Company's personal care products are sold to foreign customers, either directly or through its marketing partners.

While the Company does have competition in the marketplace for some of its products, many of its products are either unique in their field or have some unique characteristics, and therefore are not in direct competition with the products of other pharmaceutical, specialty chemical, or health care companies. Many of the Company's products are manufactured using patented or proprietary processes. The Company's research and development department is actively working on the development of new products to expand the Company's line of personal care and performance products.

The Company has been issued many patents and trademarks and intends, whenever possible, to make efforts to obtain patents in connection with its product development program.

CRITICAL ACCOUNTING POLICIES

As disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 the discussion and analysis of the Company's financial condition and results of operations are based on consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company's most critical accounting policies relate to revenue recognition, concentration of credit risk, inventory, pension costs, patents, and income taxes. Since December 31, 2007, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2007, and a comparison of the results of operations for the nine and three months ended September 30, 2008 and September 30, 2007. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2007.

RESULTS OF OPERATIONS

<u>Revenue</u>

For the nine-month period ended September 30, 2008, revenue increased \$92,407 (1.0%) as compared with the comparable period in 2007 while sales for the three-month period ended September 30, 2008 increased \$850,875 (32.1%) as compared with the three-month period ended September 30, 2007. The changes in revenue for both the nine- and three-month periods ended September 30, 2008 were principally attributable to changes in sales volumes of the following product lines:

(a) **Personal care products**: For the nine months ended September 30, 2008, the Company's sales of personal care products decreased by \$13,009 (0.2%) when compared with the nine months ended September 30, 2007. This slight decrease is due to ordering patterns of the Company's distributors.

For the three months ended September 30, 2008 the Company's sales of personal care products increased by \$610,248 (35.3%) when compared with the three months ended September 30, 2007. This increase was due primarily to an increase in sales to one of the Company's major distributors, which the Company believes was the result of its ordering and stocking patterns rather than any real increase in sales to its customers. This increase was partially offset by a decline in sales to our Korean distributor due to economic conditions in that country. Sales to our other distributors reflect both increases and decreases due to buying patterns.

(b) **Pharmaceuticals:** Pharmaceutical sales decreased \$39,637 (2.0%) for the nine months ended September 30, 2008 when compared with the comparable period in 2007, but

increased by \$247,826 (53.51%) for the three months ended September 30, 2008 compared with the same period in 2007. In the first quarter of 2007, the Company implemented a 9% price increase on its pharmaceutical products, which resulted in customers purchasing approximately five times the normal volume in February 2007 in advance of the price increase. While the Company implemented a price increase again in the first quarter of 2008, this time it was only 4%, and customers purchased only 50% more product than normal. As a result, sales of the Company's pharmaceutical products in the first quarter of 2008 were significantly lower than in the first quarter of 2007, but sales in the second and third quarters have significantly exceeded 2007 levels. The Company expects revenue from pharmaceutical sales for the full year to equal or exceed 2007 revenue.

- (c) **Medical (non-pharmaceutical) products:** Sales of the Company's medical products increased \$174,567 (13.0%) and \$51,264 (11.4%) for the nine- and three-month periods ended September 30, 2008 when compared with the comparable periods ended June 30, 2007. The Company believes that this increase is due to buying patterns of its customers.
- (d) **Industrial products:** Sales of industrial products decreased \$12,949 (13.7%) for the ninemonth period ending September 30, 2008 when compared with the comparable period in 2007. For the three months ended September 30, 2008, sales of industrial products decreased \$6,120 (17.1%) when compared with the comparable period in 2007.

In addition to the above changes in sales, net sales allowances increased \$16,565 (9.3%) for the nine months ended September 30, 2008 and increased \$52,344 (184.5%) for the three months ended September 30, 2007. The increase in these allowances for the three months ended September 30, 2008, when compared with the same period in 2007, was primarily due to increases in allowances for distribution fees and chargebacks.

Cost of Sales

Cost of sales as a percentage of sales increased to 43.9% for the nine months ended September 30, 2008 from 40.0% for the comparable period in 2007. For the three months ended September 30, 2008 cost of sales as percentage of sales increased to 46.7% from 36.8% when compared to the comparable period in 2007. The increase in costs of sales was primarily due to an increase in cost of the Company's most significant raw material, and to a lesser extent to escalating energy, transportation costs and payroll costs.

Operating Expenses

Operating expenses consist of selling, general, and administrative expenses. Operating expenses increased \$88,173 (4.7%) and \$69,685 (12.5%), respectively, for the nine and three months ended September 30, 2008 compared with the comparable periods in 2007. This increase was primarily attributable to payroll and payroll-related expenses.

Other Income

Other income decreased \$78,363 (18.2%) and \$27,605 (19.6%), respectively, for the nine and three months ended September 30, 2008 when compared with the comparable periods in 2007. This decrease was mainly attributable to a decrease in interest rates and to lower returns on investments in 2008.

Provision for Income Taxes

The provision for income taxes decreased by \$265,800 (17.9%) and \$3,700 (0.8%), respectively, for the nine and three months ended September 30, 2008 when compared with the comparable periods in 2007. These decreases are primarily due to the decreases in the effective income tax rate for both periods and to a decrease in income before taxes of \$475,272 (11.4%) for the nine months ended September 30, 2008 when compared to the comparable period in 2007. An increase in income before taxes of \$95,650 (7.6%) for the three months ended September 30, 2008 compared with the comparable period in 2007 was more than offset by the decrease in the effective tax rate in the 2008 period.

The Company's effective income tax rate decreased to 32.8% for the nine months ended September 30, 2008 compared with 35.5% for the comparable period in 2007. The effective tax rate decreased to 32.5% for the three-month period ended September 30, 2008 compared with 35.3% for the comparable period in 2007. The decreases in the effective rates are principally attributable to changes in state income tax allocation percentages. Those changes, along with changes in the Federal Domestic Production Activities Deduction, primarily account for differences in the effective income tax rate from the statutory federal income tax rate.

LIQUIDITY AND CAPITAL RESOURCES

Working capital increased by \$698,883 to \$14,099,575 at September 30, 2008 from \$13,400,692 at December 31, 2007. The current ratio increased to 13.0 to 1 at September 30, 2008 from 6.7 to 1 at December 31, 2007. The increase in the current ratio was primarily due to the effect of a decrease in dividends payable and an increase in accounts receivable, which were partially offset by other changes in working capital items.

The Company has allocated approximately \$63,000 for capital expenditures during the remainder of 2008, and believes that its working capital is and will continue to be sufficient to support its operating requirements for at least the next twelve months.

The Company generated cash from operations of \$2,494,954 and \$3,545,833 for the nine months ended September 30, 2008 and September 30, 2007, respectively. The decrease was primarily due to a decrease in income from continuing operations and increases in accounts receivable, which were partially offset by other elements of working capital.

Cash provided by investing activities for the nine-month period ended September 30, 2008 was \$86,396 while cash used in investing activities for the nine-month period ending September 30, 2007 was \$504,107. Net purchases of marketable securities and of plant equipment were reduced in the 2008 period, and liquidation of temporary investments also contributed to the increase in cash provided in 2008. This increase was primarily due to a decrease in purchases of plant equipment and a decrease in temporary investments and purchases of marketable securities.

Cash used in financing activities was \$2,726,533 and \$2,414,589 for the nine months ended September 30, 2008 and September 30, 2007, respectively. The increase was mainly due to an increase in dividends paid, with the Company paying a dividend of \$0.28 per share in the first quarter of 2008 compared with \$0.22 per share paid in the first quarter of 2007.

NEWLY ADOPTED ACCOUNTING PRONOUNCEMENTS

In October 2008, the FASB issued FASB Staff Position FAS 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active" ("FSP 157-3"), which clarified the application of FAS 157 and demonstrated how the fair value of a financial asset is determined when the market for that financial asset is inactive. FSP 157-3 was effective upon issuance. The implementation of this standard did not have an impact on the Company's financial position.

Effective January 1, 2008, the Company adopted SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS 159"). This statement provides companies with an option to report selected financial assets and liabilities at fair value. As of September 30, 2008, the Company had not elected to use the fair value option allowed by SFAS 159. The adoption of SFAS 159 did not have a material effect on the Company's consolidated financial position, results of operations, cash flows or financial statement disclosures.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In December 2007, the FASB issued Statement No. 141 (revised), "Business Combinations" ("SFAS 141 (R)"). The standard changes the accounting for business combinations including the measurement of acquired shares issued in consideration for a business combination, the recognition of contingent consideration, the accounting for pre-acquisition gain and loss contingencies, the recognition of capitalized in-process research and development, the accounting for acquisition-related restructuring cost accruals, the treatment of acquisition related transaction costs and the recognition of changes in the acquirer's income tax valuation allowance. SFAS 141(R) is effective for fiscal years beginning after December 15, 2008, with early adoption prohibited. The Company does not expect SFAS 141(R) to have a significant impact on the Company's financial position, and will evaluate the impact in the event of an acquisition.

In December 2007, the FASB issued Statement No. 160, "Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51" ("SFAS 160"). The standard changes the accounting for noncontrolling (minority) interests in consolidated financial statements including the requirements to classify noncontrolling interests as a component of consolidated stockholders' equity, and the elimination of "minority interest" accounting in results of operations with earnings attributable to noncontrolling interests reported as part of consolidated earnings. Additionally, SFAS 160 revises the accounting for both increases and decreases in a parent's controlling ownership interest. SFAS 160 is effective for fiscal years beginning after December 15, 2008. with early adoption prohibited. The Company is currently evaluating the effect, if any, the adoption will have on the Company's financial position and results of operations, but does not expect the adoption of SFAS 160 to have a significant impact on the Company's financial position.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off balance sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The information to be reported under this item is not required of smaller reporting companies.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information to be reported under this item is not required of smaller reporting companies.

Item 4T. CONTROLS AND PROCEDURES

(a) DISCLOSURE CONTROLS AND PROCEDURES

The Company's management, including its Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the "Exchange Act"). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company's management, including its Principal Executive Officer and Principal Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company's disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

(b) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company's Principal Executive Officer and Principal Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. They have also concluded that there were no significant changes in the Company's internal controls after the date of the evaluation.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

NONE

ITEM 1A. RISK FACTORS

The information to be reported under this item is not required of smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

NONE

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

NONE

ITEM 5. OTHER INFORMATION

NONE

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

- 31.1 Certification of Kenneth H. Globus, President and principal executive officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Kenneth H. Globus, President and principal executive officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K

There were two reports on Form 8-K filed during the fiscal quarter ended September 30, 2008. The first was filed on July 14, 2008, and related to the issuance of a press release announcing that the Company's stock had been added to the Russell Microcap Index. The second was filed on August 12, 2008 and related to the issuance of a press release on August 12, 2008 that announced the Company's financial results for the fiscal quarter ended June 30, 2008.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UNITED-GUARDIAN, INC. (Registrant)

By: /S/ KENNETH H. GLOBUS Kenneth H. Globus President

By: <u>/S/ ROBERT S. RUBINGER</u>
Robert S. Rubinger
Chief Financial Officer

Date: November 11, 2008